Best Evidence Analyses and Commentary

Prescrire Internation Evaluation of Febuxostat (Uloric)
April 16, 2009

Attached is the Prescrire International evaluation of the new xanthine oxidase inhibitor febuxostat.

Prescrire International is the English language version of Prescrire a French drug newsletter that has been published for the past 30 years. Prescrire is highly regarded for its independence.

There have been two head-to-head trials of febuxostat versus allopurinol published. In these trials based on a composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and non-fatal cardiac arrest, the incidence was 4 to 5 times higher with febuxostat than with allopurinol.

Treatment withdrawals in these trials due to hepatic abnormalities were 2.8% versus 0.4% with febuxostat and allopurinol respectively.

To download this article in PDF format, click here

Don't have Adobe Reader? Click here or the graphic to download it.

Website Terms of Use Disclaimer | E-mail Terms of Use | Contact LECOM | RSS | Copyright © 2009 LECOM - All rights reserved